MK-4409

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
MK-4409
MK-4409 structure.svg
Clinical data
ATC code
  • None
Legal status
Legal status
Identifiers
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC22H17FN3O2S
Molar mass441.905 g/mol g·mol−1
3D model (JSmol)

MK-4409 is a drug which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 11nM, and both analgesic and antiinflammatory effects in animal studies. It was developed for the treatment of neuropathic pain and has progressed as far as early stage human clinical trials.[1][2]

See also[edit]

References[edit]

  1. ^ Chobanian; et al. (10 April 2014). "Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain". ACS Med. Chem. Lett. 5 (6): 717–721. doi:10.1021/ml5001239. PMC 4060928. PMID 24944750.
  2. ^ Merck (15 October 2009). "Merck Pipeline, Oct 2009" (PDF). Merck.